CA2737447A1 - Hayley's comet - Google Patents
Hayley's comet Download PDFInfo
- Publication number
- CA2737447A1 CA2737447A1 CA 2737447 CA2737447A CA2737447A1 CA 2737447 A1 CA2737447 A1 CA 2737447A1 CA 2737447 CA2737447 CA 2737447 CA 2737447 A CA2737447 A CA 2737447A CA 2737447 A1 CA2737447 A1 CA 2737447A1
- Authority
- CA
- Canada
- Prior art keywords
- cultivar
- cbd
- cannabinoid
- cannabidiolic acid
- strains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/6895—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
A new cultivar of medicinal cannabis has been bred that renders large amounts of cannabidiolic acid (mg/gram ground flower weight)... greater than 10%. The cultivar moved from an outdoor to indoor environment produced similar levels of cannabidiolic (CBD) and similar cannabinoid profiles. Reproduced asexually, the same (greater than 10%) cannabidiolic acid amounts were rendered and this remains constant crop to crop.
THC levels do not change between 20 and 30% of that of the CBD-A
concentration.
High Pressure Liquid Chromatography (HPLC) determines Cannabinoid profiles where the amounts of the three most abundant cannabinoids (tetrahydrocannabinol, cannabinol and cannabidiol) and their acids are quantified. The cannabinoid profile relates directly to the physiological effects of the plant as a medicine. In addition, a genetic fingerprint of the strain has been generated using gel electrophoresis. Strains high in cannabidiolic acid are rare since commercial breeding has led to strains with large concentrations of tetrahydrocannabinol (THC) and very little cannabidiol making the strain in question rare. Hayley's Comet provides a unique cannabinoid profile containing large concentrations of CBD-A making it useful for medicaments for seizure disorder, pain and inflammation.
THC levels do not change between 20 and 30% of that of the CBD-A
concentration.
High Pressure Liquid Chromatography (HPLC) determines Cannabinoid profiles where the amounts of the three most abundant cannabinoids (tetrahydrocannabinol, cannabinol and cannabidiol) and their acids are quantified. The cannabinoid profile relates directly to the physiological effects of the plant as a medicine. In addition, a genetic fingerprint of the strain has been generated using gel electrophoresis. Strains high in cannabidiolic acid are rare since commercial breeding has led to strains with large concentrations of tetrahydrocannabinol (THC) and very little cannabidiol making the strain in question rare. Hayley's Comet provides a unique cannabinoid profile containing large concentrations of CBD-A making it useful for medicaments for seizure disorder, pain and inflammation.
Description
Table 1: Genetic Profile of Hayley's comet Cind 16FR (bp) Cind1FR Cind5 Cind24FR
Ha le 's comet 84 88 90 104 108 214 224 215 324 144 167 Cindl 96 102 108 214 214 173 226 221 221 Blueberry 88 90 102 108 212 212 220 320 193 193 U pick 88 90 108 110 226 226 200 320 187 187 Table 1: demonstrates the 4-locus DNA profile (Cind1FR, Cind5FR, Cindl6FR, and Cind24FR) for Hayley's comet. Across the table the differences in fragment size for the 4 plants compared (HC, Cindl, Blueberry and Upick). Each number corresponds to an 'allele' located in the cannabis genome. One locus is complex (Cind16FR) and gives rise to more than two alleles (3-5) while the other three loci (1,5,and 24) are typical diploids, either homozygous where allele sizes are the same, or heterozygous where the two allele are different.
Claim 9: The cultivar (Hayley's Comet), described here provides a cannabinoid profile useful in the treatment of epilepsy.
Background of the Invention:
Patent No. 2694325 speaks to synthetic analogues of Cannabidiol; the invention described here refers to natural cannabidiolic acid compounds and their decarboxylated derivatives.
Patent No. 2499210 speaks to cannabidiol in a highly pure form, greater than 95%, that can be used in medical studies, whereas the invention described here is a means of obtaining cannabidiolic acid in its natural form, plus inclusion of the other natural cannabinoids.
Patent No. 2411831 speaks to uses of cannabidiol in pure form; the invention described here addresses cannabidiolic acid in its natural form and means of obtaining it.
Patent No. 2424356 speaks to extraction of tetrahydrocannabinol and cannabidiol using super critical fluid extraction whereas the invention described here employs no extraction of the compounds from the plant.
Patent No. 2692539 speaks to ratios of cannabidiol to cannabivarin as antagonists to the CB 1 and CB2 receptors, whereas the invention described here is merely a continued source of cannabidiolic acid and other carboxylated cannabinoids.
A strain with high concentrations of cannabidiolic acid was bred, whereby with asexual reproduction cannabidiolic acid concentrations (as determined by HPLC) remain consistent and the genetic fingerprint remains inimitable within cannabis sub-species.
The DNA profile was generated using (methodology) and compared to a number of common strains of similar type. The unique DNA finger-print plus the cannabinoid profile characterize the strain, plus morphological description, cloning, growth and pest resistance add to distinguishing this plant from others of its type.
Objectives of the Invention:
1.) An objective of the invention is to preserve a strain of cannabis with unique cannabinoid and DNA profiles, represented by high cannabidiolic acid to tetrahydrocannabinolic acid ratios.
Ha le 's comet 84 88 90 104 108 214 224 215 324 144 167 Cindl 96 102 108 214 214 173 226 221 221 Blueberry 88 90 102 108 212 212 220 320 193 193 U pick 88 90 108 110 226 226 200 320 187 187 Table 1: demonstrates the 4-locus DNA profile (Cind1FR, Cind5FR, Cindl6FR, and Cind24FR) for Hayley's comet. Across the table the differences in fragment size for the 4 plants compared (HC, Cindl, Blueberry and Upick). Each number corresponds to an 'allele' located in the cannabis genome. One locus is complex (Cind16FR) and gives rise to more than two alleles (3-5) while the other three loci (1,5,and 24) are typical diploids, either homozygous where allele sizes are the same, or heterozygous where the two allele are different.
Claim 9: The cultivar (Hayley's Comet), described here provides a cannabinoid profile useful in the treatment of epilepsy.
Background of the Invention:
Patent No. 2694325 speaks to synthetic analogues of Cannabidiol; the invention described here refers to natural cannabidiolic acid compounds and their decarboxylated derivatives.
Patent No. 2499210 speaks to cannabidiol in a highly pure form, greater than 95%, that can be used in medical studies, whereas the invention described here is a means of obtaining cannabidiolic acid in its natural form, plus inclusion of the other natural cannabinoids.
Patent No. 2411831 speaks to uses of cannabidiol in pure form; the invention described here addresses cannabidiolic acid in its natural form and means of obtaining it.
Patent No. 2424356 speaks to extraction of tetrahydrocannabinol and cannabidiol using super critical fluid extraction whereas the invention described here employs no extraction of the compounds from the plant.
Patent No. 2692539 speaks to ratios of cannabidiol to cannabivarin as antagonists to the CB 1 and CB2 receptors, whereas the invention described here is merely a continued source of cannabidiolic acid and other carboxylated cannabinoids.
A strain with high concentrations of cannabidiolic acid was bred, whereby with asexual reproduction cannabidiolic acid concentrations (as determined by HPLC) remain consistent and the genetic fingerprint remains inimitable within cannabis sub-species.
The DNA profile was generated using (methodology) and compared to a number of common strains of similar type. The unique DNA finger-print plus the cannabinoid profile characterize the strain, plus morphological description, cloning, growth and pest resistance add to distinguishing this plant from others of its type.
Objectives of the Invention:
1.) An objective of the invention is to preserve a strain of cannabis with unique cannabinoid and DNA profiles, represented by high cannabidiolic acid to tetrahydrocannabinolic acid ratios.
2.) A further objective of the invention is to preserve a strain of cannabis with high ratios CBD-A to THC-A to be used in medicaments.
3.) A further objective of the invention is to propagate the strain for yields of CBD-A.
4.) A further objective of the invention is to propagate the strain for use in medicaments for chronic pain and seizure disorder.
5.) A further objective of the invention is to propagate a strain with consistent cannabinoid profiles of high CBD-A to THC-A ratios.
6.) A further objective of the invention is to use this strain to breed other strains with a high CBD-A to THC-A ratio.
Summary of the Invention:
A single cultivar of cannabis has been bred with distinct HPLC and DNA
profiles.
The cultivar is asexually reproduced with cloning such that a cannabinoid profile with greater than 100 mg/gram (of ground flower weight) CBD-A is consistently produced and the THC concentration consistently less than 150 mg/gram, of ground flower weight.
Summary of the Invention:
A single cultivar of cannabis has been bred with distinct HPLC and DNA
profiles.
The cultivar is asexually reproduced with cloning such that a cannabinoid profile with greater than 100 mg/gram (of ground flower weight) CBD-A is consistently produced and the THC concentration consistently less than 150 mg/gram, of ground flower weight.
Claims (8)
- Claim 1: A method whereby a unique cannabinoid profile as determined by High Pressure Liquid Chromatography (HPLC), defines a specific cultivar of asexually reproducing cannabis.
- Claim 2: A method whereby a genetic profile (fingerprint), defines a specific cultivar of asexually reproducing cannabis.
- Claim 3: A method whereby a cannabidiolic acid concentration of greater than mg/gram (of ground flower weight), is consistently found in the specific cultivar of
- Claim 4: A method whereby a tetrahydrocannabinol concentration of less than 15% (of ground flower weight), is consistently found in the specific cultivar of asexually reproducing cannabis.
- Claim 5: A method whereby the DNA profile at locus Cind 16FR (bp) differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
- Claim 6: A method whereby the DNA profile at locus Cind1FR differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
- Claim 7: A method whereby the DNA profile at locus Cind5 differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
- Claim 8: A method whereby the DNA profile at locus Cind24FR differs from other comparable strains and having a distinct fragment pattern characteristic of the cultivar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2737447 CA2737447A1 (en) | 2011-04-27 | 2011-04-27 | Hayley's comet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2737447 CA2737447A1 (en) | 2011-04-27 | 2011-04-27 | Hayley's comet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2737447A1 true CA2737447A1 (en) | 2012-10-27 |
Family
ID=47070977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2737447 Abandoned CA2737447A1 (en) | 2011-04-27 | 2011-04-27 | Hayley's comet |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2737447A1 (en) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| US12121499B2 (en) | 2011-09-29 | 2024-10-22 | Gw Pharma Ltd. | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
-
2011
- 2011-04-27 CA CA 2737447 patent/CA2737447A1/en not_active Abandoned
Cited By (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US12121499B2 (en) | 2011-09-29 | 2024-10-22 | Gw Pharma Ltd. | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US11963937B2 (en) | 2014-06-17 | 2024-04-23 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11311498B2 (en) | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10849860B2 (en) | 2014-10-14 | 2020-12-01 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10092525B2 (en) | 2014-10-14 | 2018-10-09 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
| US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10111840B2 (en) | 2014-10-14 | 2018-10-30 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US10137095B2 (en) | 2014-10-14 | 2018-11-27 | Gw Pharma Limited | Use of cannabinoids in the treatment of epilepsy |
| US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US12064399B2 (en) | 2015-06-17 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Use of cannabinoids in the treatment of epilepsy |
| US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| AU2016305545B2 (en) * | 2015-08-10 | 2021-12-09 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| EP3769755A1 (en) | 2015-08-10 | 2021-01-27 | GW Research Limited | Use of cannabidiolic acid in the treatment of epilepsy |
| US11684598B2 (en) | 2015-08-10 | 2023-06-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
| US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
| US12064398B2 (en) | 2016-07-01 | 2024-08-20 | Jazz Pharmaceuticals Research Uk Limited | Parenteral formulations |
| US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
| US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
| US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
| US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
| US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
| US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US12102619B2 (en) | 2020-02-27 | 2024-10-01 | Jazz Pharmaceuticals Research Uk Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2737447A1 (en) | Hayley's comet | |
| CA2859934A1 (en) | Hayley's comet ii | |
| Dimopoulos et al. | Drought stress modulates cuticular wax composition of the grape berry | |
| Mikulic-Petkovsek et al. | Investigation of anthocyanin profile of four elderberry species and interspecific hybrids | |
| Kurilich et al. | Quantification of Carotenoid and Tocopherol Antioxidants in Zea m ays | |
| Van Bakel et al. | The draft genome and transcriptome of Cannabis sativa | |
| US10441617B2 (en) | Breeding, production, processing and use of medical cannabis | |
| Vignesh et al. | Genetic variability for kernel b-carotene and utilization of crtRB1 3’TE gene for biofortification in maize (Zea mays L.) | |
| Gao et al. | Supplementation of xanthophylls decreased proinflammatory and increased anti-inflammatory cytokines in hens and chicks | |
| Aicha et al. | Rapid in vitro regeneration and clonal multiplication of Thymus bleicherianus Pomel, a rare and threatened medicinal and aromatic plant in Morocco | |
| Mu et al. | Oil content and fatty acid composition of the kernels of 31 genotypes of Chinese dwarf cherry [Cerasus humilis (Bge.) Sok.] | |
| Dowell et al. | Genome-wide association mapping of floral traits in cultivated sunflower (Helianthus annuus) | |
| Xu et al. | Herbivory-induced emission of volatile terpenes in Chrysanthemum morifolium functions as an indirect defense against Spodoptera litura larvae by attracting natural enemies | |
| Kar et al. | Micropropagation, genetic fidelity assessment and phytochemical studies of Clerodendrum thomsoniae Balf. f. with special reference to its anti-stress properties | |
| Jakhar et al. | Effect of antioxidants on in vitro degree of browning and culture establishment of Guggul [Commiphora wightii (Arnott)]: A valuable desert medicinal plant | |
| de Oliveira Prudente et al. | Goji berry (Lycium barbarum L.) in vitro multiplication improved by light-emitting diodes (LEDs) and 6-benzylaminopurine | |
| CN106172520A (en) | Mosquito-repellent water | |
| CN105230410A (en) | Method for preventing and treating sugarcane pokkah boeng disease | |
| Basuki | Analisis tingkat preferensi petani terhadap karakterisitik hasil dan kualitas bawang merah varietas lokal dan impor | |
| US20080209584A1 (en) | Pepper Plants Having Fruit With Altered Vitamin Content | |
| Panjeshahin et al. | Genetic and morphological diversity of wild mint | |
| EP3300474A1 (en) | Betacryptoxanthin compositions, processes for preparation and uses thereof | |
| CN106069786B (en) | A method of anti-browning and promotion adventitious buds differentiation in eucalyptus tissue cultures | |
| US11240978B2 (en) | Hemp variety NBS CBD-1 | |
| Quiles et al. | Coenzyme Q differentially modulates phospholipid hydroperoxide glutathione peroxidase gene expression and free radicals production in malignant and non-malignant prostate cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20140429 |